|Mr. Nick Leschly||Chief Exec. Officer, Pres and Director||814.62k||732.07k||44|
|Mr. Jeffrey T. Walsh MBA||Chief Financial & Strategy Officer and Principal Financial Officer||568.05k||N/A||51|
|Ms. Susanna Gatti High||Chief Operating Officer||16.63k||N/A||49|
|Dr. Philip D. Gregory D. Phil.||Chief Scientific Officer||622.15k||N/A||46|
|Dr. David M. Davidson M.D.||Chief Medical Officer||554.35k||299.61k||53|
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companys lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 5. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 6; Compensation: 6.